Related Experiment Video
Updated: Aug 15, 2026

Cutoff Value of Phase Angle by Bioelectrical Impedance Analysis at Admission as a Prognostic Factor in Patients with Acute Heart Failure
Published on: June 10, 2025
BNP in the diagnosis and risk stratification of heart failure
1Division of Cardiology, St Michael's Hospital, University of Toronto, Toronto, ON, Canada.
Insights
Brain natriuretic peptide (BNP) and NT-proBNP are valuable biomarkers for diagnosing heart failure (HF) and predicting patient outcomes. Testing these peptides can aid in HF diagnosis and management.
Area of Science:
- Cardiology
- Biomarkers
- Heart Failure Research
Background:
- Heart failure (HF) presents diagnostic challenges with conventional methods.
- Cardiac natriuretic peptides, like BNP, are crucial biomarkers for cardiac function.
- BNP and NT-proBNP are linked to HF diagnosis, prognosis, and mortality.
Purpose of the Study:
- To highlight the diagnostic and prognostic utility of BNP and NT-proBNP in heart failure.
- To discuss the role of natriuretic peptides in cardiovascular disorders.
- To explore the potential of BNP/NT-proBNP testing in optimizing HF management.
Main Methods:
- Observational studies establishing associations between plasma BNP/NT-proBNP and HF.
- Analysis of preliminary data from randomized controlled trials on biomarker-guided therapy.
- Consideration of confounding variables in biomarker interpretation.
Main Results:
- Plasma BNP and NT-proBNP levels strongly correlate with HF diagnosis.
- These biomarkers independently predict mortality and HF events.
- Preliminary trial data suggest BNP/NT-proBNP levels can optimize HF patient management.
Conclusions:
- BNP and NT-proBNP are essential tools for HF diagnosis and prognosis.
- Careful clinical application of these biomarkers is highly beneficial.
- Ongoing large-scale trials will further define the role of BNP/NT-proBNP-guided HF therapy.
Abstract:
Heart failure (HF) is a common disorder that is associated with significant mortality and morbidity. However, the diagnosis of HF may at times be difficult when using conventional tools. The cardiac natriuretic peptides, particularly brain (B-type) natriuretic peptide (BNP), have evolved to be useful biomarkers of cardiac function and prognosis in HF and other cardiovascular disorders. Multiple observational studies have established the close association between plasma BNP as well as the N-terminal fragment of the BNP prohormone (NT-proBNP) with the diagnosis of HF and an independent prediction of mortality and HF events. Although there are confounding variables to consider, when used in the correct clinical settings, BNP or NT-proBNP testing can be extremely useful. Furthermore, preliminary data from randomized controlled trials suggest that knowledge of BNP and/or NT-proBNP level may optimize the management of patients with HF. Large-scale randomized controlled trials that evaluate BNP/NT-proBNP-guided therapy are ongoing.
Related Concept Videos
Heart Failure IV: Classification and Diagnostic Evaluation
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
Heart Failure VII: Nursing Interventions
Pathophysiology of Heart Failure
Heart Failure II: Pathophysiology
Heart Failure I: Introduction
